Deutsche Bank AG Has $2.29 Million Holdings in Neogen Co. (NASDAQ:NEOG)

Deutsche Bank AG raised its stake in shares of Neogen Co. (NASDAQ:NEOG - Free Report) by 52.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 188,609 shares of the company's stock after buying an additional 65,293 shares during the period. Deutsche Bank AG owned about 0.09% of Neogen worth $2,290,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Barclays PLC grew its stake in shares of Neogen by 129.8% in the 3rd quarter. Barclays PLC now owns 366,753 shares of the company's stock valued at $6,165,000 after buying an additional 207,160 shares in the last quarter. Inspire Investing LLC lifted its stake in Neogen by 30.9% in the fourth quarter. Inspire Investing LLC now owns 36,383 shares of the company's stock valued at $442,000 after acquiring an additional 8,580 shares during the last quarter. Blue Trust Inc. grew its position in Neogen by 196.7% in the fourth quarter. Blue Trust Inc. now owns 3,368 shares of the company's stock worth $41,000 after acquiring an additional 2,233 shares in the last quarter. KBC Group NV increased its stake in shares of Neogen by 39.1% during the 4th quarter. KBC Group NV now owns 8,464 shares of the company's stock worth $103,000 after purchasing an additional 2,379 shares during the last quarter. Finally, American Capital Advisory LLC increased its stake in shares of Neogen by 291.6% during the 4th quarter. American Capital Advisory LLC now owns 53,213 shares of the company's stock worth $646,000 after purchasing an additional 39,623 shares during the last quarter. 96.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Neogen news, insider Amy M. Rocklin purchased 12,500 shares of the firm's stock in a transaction on Wednesday, April 23rd. The shares were purchased at an average price of $4.99 per share, for a total transaction of $62,375.00. Following the completion of the purchase, the insider now directly owns 36,287 shares of the company's stock, valued at approximately $181,072.13. This represents a 52.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Aashima Gupta acquired 16,000 shares of the company's stock in a transaction dated Monday, May 12th. The stock was acquired at an average price of $6.25 per share, with a total value of $100,000.00. Following the purchase, the director now owns 21,917 shares in the company, valued at approximately $136,981.25. This represents a 270.41% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 83,500 shares of company stock valued at $431,525 over the last three months. 1.13% of the stock is owned by corporate insiders.

Neogen Stock Performance

NEOG traded down $0.12 during trading on Wednesday, hitting $6.04. The stock had a trading volume of 205,428 shares, compared to its average volume of 3,047,757. The firm has a market cap of $1.31 billion, a PE ratio of -2.76 and a beta of 1.83. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33. Neogen Co. has a 12 month low of $3.87 and a 12 month high of $18.58. The company has a 50 day simple moving average of $6.33 and a 200-day simple moving average of $9.92.

Neogen (NASDAQ:NEOG - Get Free Report) last posted its quarterly earnings data on Wednesday, April 9th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). The business had revenue of $221.00 million for the quarter, compared to analyst estimates of $225.27 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. Neogen's revenue for the quarter was down 3.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 EPS. Analysts expect that Neogen Co. will post 0.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on NEOG. Guggenheim lowered their target price on shares of Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Piper Sandler lowered their price objective on Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a report on Tuesday, April 22nd.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.